Evidence map›Paper›PMID 33404088›Full record

Observational studyCancer science2020

Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.

Takaaki Ono, Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Lifelong TKI therapy: how to manage cardiovascular and other risks.Hematology. American Society of Hematology. Education Program · 2021
    Review
  10. Review
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 1 country.

Takaaki OnoDivison of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan.ORCID https://orcid.org/0000-0003-3922-7432
Naoto TakahashiDepartment of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, Akita, Japan.ORCID https://orcid.org/0000-0002-6758-3787
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Tatsuya KawaguchiKumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
Ritsuro SuzukiDepartment of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.ORCID https://orcid.org/0000-0002-5974-7614
Kazuhito YamamotoDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.ORCID https://orcid.org/0000-0002-8588-8955
Kazunori OhnishiTokai-Hokuriku Block Blood Center, Seto, Japan.
Tomoki NaoeNational Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.ORCID https://orcid.org/0000-0003-2818-4270
Aichi Cancer Center · JPAkita University · JPHamamatsu University School of Medicine · JPHokuriku Electric Power Company (Japan) · JPKindai University Hospital · JPKumamoto University · JPNational Hospital Organization · JPShimane University Hospital · JPSocial Insurance Saitama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comorbidities at diagnosis among patients with chronic myeloid leukemia in chronic phase (CML-CP) may affect their overall survival (OS) rate even in the tyrosine kinase inhibitor (TKI) era. However, the prognostic impact of comorbidities in patients with CML-CP treated with a second-generation TKI (2GTKI) has not been elucidated. We evaluated the effect of comorbidities on survival using the Charlson Comorbidity Index (CCI) in patients with CML-CP treated with imatinib or a 2GTKI (nilotinib and dasatinib). From April 2010 to March 2013, 506 patients with CML-CP were registered for the population-based cohort study, and 452 with a median age of 56 y were assessable. Treatment groups included 139 patients receiving imatinib, 169 receiving nilotinib, and 144 receiving dasatinib. Comorbidities were diagnosed in 99 patients. CCI scores were stratified as follows: 2, 353 patients; 3, 72 patients; and ≥4, 27 patients. Treatment response did not vary relative to CCI scores. However, across the entire cohort, the OS rate was significantly lower among patients with higher CCI scores than in those with a CCI score of 2 (94.4% in score 2, 89.0% in score 3, and 72.8% in score ≥4; P < .001). Multivariate analysis identified a CCI score of ≥4 as a strong adverse prognostic factor for OS rather than the disease-specific risk factor, older age, performance status, or selection of TKI (Wald test, P < .01). Our results demonstrated that comorbidities at diagnosis were the most important predictive factor for successful treatment, regardless of the TKI type used in CML-CP. This trial was registered at UMIN-CTR as 00003581.

Indexed as

AdolescentAdultAgedAged, 80 and overCohort StudiesComorbidityDasatinibFemaleHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrognosisProtein Kinase InhibitorsProtein-Tyrosine KinasesDasatinibImatinib MesylatenilotinibProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidineschronic myeloid leukemiacomorbiditydasatinibimatinibnilotinib

Identifiers

PMID33404088
PMCPMC7541002
OpenAlexW3044242018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.